Objective To investigate the expression levels of serum fibronectin(FN)in patients with non-small cell lung cancer(NSCLC)and evaluate its clinical diagnostic significance.Methods Firstly,the gene and tissue protein expression levels of FN in NSCLC were assessed using the TIMER2.0 database,GTEx database,and Human Protein Atlas(HPA)database.Secondly,from January 2021 to June 2023,a total of 154 patients with lung space-occupying lesions or shadows at the First Affiliated Hospital of Anhui University of Chinese Medicine were enrolled.Based on medical history,clinical manifestations,imaging tests,and pathological histological find-ings,these patients were categorized into two groups:81 patients with NSCLC and 73 patients with benign lung diseases.The serum concentration of FN was measured by immunoturbidimetry,while the serum levels of CEA,SCC,and CYFRA21-1 were determined using chemiluminescence.Results The bioinformatics analysis results demonstrated that the gene expression and tissue protein levels of FN were significantly reduced compared to normal tissues.In serological evaluations,serum FN concentrations in patients with advanced NSCLC(Stage Ⅲ-Ⅳ)and early-stage NSCLC(Stage Ⅰ-Ⅱ)(249.50 ng/mL and 305.00 ng/mL,respectively)were markedly lower than those observed in the benign lung disease group(429.16 ng/mL)(P<0.001).Univariate and multivariate logistic regression analyses indicated that serum FN could serve as a significant predictor for the presence of NSCLC.The area under the receiver operating characteristic curve(ROC)for serum FN in diagnosing early-stage NSCLC was 0.790,which outperformed CEA(0.618),SCC(0.653),and CYFRA21-1(0.601).The optimal critical concen-tration of serum FN for distinguishing early-stage NSCLC from benign diseases was determined to be 347.6 ng/mL,with a sensitivity of 71.93％,surpassing that of CEA(19.30％),SCC(12.28％),and CYFRA21-1(8.77％).Conclusion Serum FN is significantly downregulated in NSCLC and may serve as a potential biomarker for the early diagnosis of NSCLC.

Objective To investigate the expression levels of serum fibronectin(FN)in patients with non-small cell lung cancer(NSCLC)and evaluate its clinical diagnostic significance.Methods Firstly,the gene and tissue protein expression levels of FN in NSCLC were assessed using the TIMER2.0 database,GTEx database,and Human Protein Atlas(HPA)database.Secondly,from January 2021 to June 2023,a total of 154 patients with lung space-occupying lesions or shadows at the First Affiliated Hospital of Anhui University of Chinese Medicine were enrolled.Based on medical history,clinical manifestations,imaging tests,and pathological histological find-ings,these patients were categorized into two groups:81 patients with NSCLC and 73 patients with benign lung diseases.The serum concentration of FN was measured by immunoturbidimetry,while the serum levels of CEA,SCC,and CYFRA21-1 were determined using chemiluminescence.Results The bioinformatics analysis results demonstrated that the gene expression and tissue protein levels of FN were significantly reduced compared to normal tissues.In serological evaluations,serum FN concentrations in patients with advanced NSCLC(Stage Ⅲ-Ⅳ)and early-stage NSCLC(Stage Ⅰ-Ⅱ)(249.50 ng/mL and 305.00 ng/mL,respectively)were markedly lower than those observed in the benign lung disease group(429.16 ng/mL)(P<0.001).Univariate and multivariate logistic regression analyses indicated that serum FN could serve as a significant predictor for the presence of NSCLC.The area under the receiver operating characteristic curve(ROC)for serum FN in diagnosing early-stage NSCLC was 0.790,which outperformed CEA(0.618),SCC(0.653),and CYFRA21-1(0.601).The optimal critical concen-tration of serum FN for distinguishing early-stage NSCLC from benign diseases was determined to be 347.6 ng/mL,with a sensitivity of 71.93％,surpassing that of CEA(19.30％),SCC(12.28％),and CYFRA21-1(8.77％).Conclusion Serum FN is significantly downregulated in NSCLC and may serve as a potential biomarker for the early diagnosis of NSCLC.

ObjectiveTo explore the effect of cluster needing of scalp point combined with rehabilitation techniques on acute cerebral infarction patient's movement disturbance.MethodsFugl-Meyer Measure, Bathel Index, Nerve function disturbance and clinical effect assessment methods were used to assess the motion function and daily living activity of cluster needling of scalp point group, rehabilitation group and cluster needling of scalp point combined with rehabilitation group.ResultsThe motion function and daily living activity of the cluster needling of scalp point combined with rehabilitation group patients were superior to cluster needling of scalp point group patients and rehabilitation group patients (P<0.01,P<0.05). The total effective rate can reach to 97.14%. Otherwise, cluster needling of scalp point combined with rehabilitation could also prevent food drop or inversion, subluxation of acromioclavicular joint, shoulder-hand syndrome, contracture of joint, mistake-use syndrome and abnormal motor mode.ConclusionThe cluster needling of scalp point combined with rehabilitation can improve the patients' living quality effectively.